Objective: Chronic rhinosinusitis (CRS) can be classified as CRS with nasal polyps (CRSwNP) and CRS without nasal
polyps (CRSsNP). The aim of this study was to evaluate and compare the Systemic Immune-Inflammation Index (SII)
and Pan-I mmune -Infl ammat ion Value (PIV) levels of patients diagnosed with chronic rhinosinusitis (CRS) with nasal
polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP) along with healthy controls.
Methods: The study analyzed 320 patients from 2022 to 2023. Patients were divided into three groups. 110 CRSwNP
patients, 110 CRSsNP patients, and 100 healthy individuals were included in Groups A, B, and C, respectively. SII and
PIV levels were assessed after CRSwNP or CRSsNP diagnosis. The values of complete blood count, SII, and PIV were
compared.
Results: The mean SII levels of patients in groups A, B, and C were 685.3 ± 641.3; 1034.18 ± 1083.12; and 532.18 ±
310.77, respectively. The mean SII levels were significantly higher in group B compared to groups A and C (P = .012 and
P = .000). The mean PIV levels of patients in groups A;B and C were 405.31 ± 486.15; 539.08 ± 599.63; and 311.29 ±
217.52, respectively. The mean PIV levels were significantly higher in group B compared to group C (P = 0.001). Results
of the ROC analyses for both SII and PIV were statistically significant. Patients with an SII cut-of value of 278.6 had a
sensitivity of 91% and sensitivity 91%, specificity of 90%. Patients with a PIV cut-off value of 117.51 had a sensitivity of
92% and sensitivity 92%, specificity of 90%.
Conclusions: SII and PIV, which are important inflammatory markers, especially in systemic inflammation, were sig-
nificantly elevated in CRSwNP patients compared to CRSsNP patients and healthy controls. This may support the pres-
ence of chronic mucosal inflammation in CRSwNP patients. However, SII and PIV are indirect markers of inflammation,
and further studies with larger patient groups are warranted.
Rhinosinusitis Chronic rhinosinusitis Inflammation Systemic immune inflammation index Pan-immune-inflammation value
| Primary Language | English |
|---|---|
| Subjects | Otorhinolaryngology |
| Journal Section | Research Article |
| Authors | |
| Submission Date | April 3, 2024 |
| Acceptance Date | July 25, 2024 |
| Publication Date | August 20, 2024 |
| Published in Issue | Year 2024 Volume: 7 Issue: 2 |
You can find the current version of the Instructions to Authors at: https://www.eurjrhinol.org/en/instructions-to-authors-104
Starting on 2020, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International
License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license
allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in
the journal.
The content published before 2020 was licensed under a traditional copyright, but the archive is still available for free access.